Mast cells emerge as mediators of atherosclerosis: Special emphasis on IL-37 inhibition. Issue 3 (June 2017)

• Record Type: Journal Article
• Authors: Conti, Pio; Lessiani, Gianfranco; Kritas, Spyridon K.; Ronconi, Gianpaolo; Caraffa, Aessandro; Theoharides, Theoharis C.
• Is Part Of: Tissue & cell. Volume 49:Issue 3(2017)
• Page Start: 393
• Page End: 400
• Publication Date: 2017-06
• Subjects: Atherosclerosis -- Lipids -- Cytokines -- Mast cells -- Il-1 -- TNF -- IL-37; Cytology -- Periodicals; 571.5
• DOI: 10.1016/j.tice.2017.04.002
• Languages: English
• ISSNs: 0040-8166

Abstract

Highlights: IL-37 cytokine inhibitor of inflammatory response. Athersclerosis is mediated by immune cells including mast cells. New frontier for inhibition of inflammation. Abstract: In atherosclerosis lipoproteins stimulate the innate immune response, leading to the release of inflammatory cytokines and chemokines. Hypercholesterolemia may activate the synthesis and release of inflammatory cytokines such as IL-1, which induces TNF release in mast cells (MCs). IL-1 and IL-1 family members orchestrate a broadening list of inflammatory diseases, including atherosclerosis. MCs are implicated in the pathophysiology of several diseases including allergy and inflammation. Activated MCs, located perivascularly, contribute to inflammation in atherosclerosis by producing inflammatory cytokines. MC IL-1-activation leads to the immediate release of inflammatory chemical mediators and TNF, and late inflammatory compounds such as cytokines. MCs can be activated by exogenous cytokines, antigens, microbial products (LPS) and neurotransmitters and generate IL-1 beta, TNF and several other inflammatory cytokines/chemokines along with PGD2, leukotrienes, histamine and proteases. MCs activated with IL-1 induce selective release of IL-6 without degranulation. TNF emerges as one of the most potent inflammatory cytokines involved in the response due to LDL. Cytokines, such as IL-1, IL-6, IL-33 and TNF, are generated in the inflammatory sites by both macrophages and MCs, mediating atherosclerosis. IL-37 (IL-1 family member 7) binds IL-18Ra chain and acts by an intracellular mechanism down-regulating the expression of pro-inflammatory signals cJun, MAP kinase p38a, STAT transcription factors and p53. Blocking IL-1 with IL-37 alleviates the symptoms in patients with inflammatory diseases including arteriosclerosis. The impact of IL-37 on inflammatory cytokines mediating atherosclerosis is beneficial and protective. However, more studies are needed to better define this mechanism and the safety and tolerability of IL-37.